Of note, autoimmune-like manifestations such as vitiligo or uveitis have been reported following TIL therapy where the infused TIL contained a population of MART-1 reactive CD8+ TIL and have been associated with clinical response.41 The gene discussed is MLANA; the disease is vitiligo.